Arcturus Therapeutics Advances Phase 2 Studies for ARCT-032 and ARCT-810 in Treating Cystic Fibrosis and Urea Cycle Disorder

Monday, 1 July 2024, 20:59
Arcturus Therapeutics is progressing with the IND filing for a phase 2 study of ARCT-032 aimed at cystic fibrosis treatment. Additionally, the company is broadening the phase 2 program for ARCT-810 focusing on urea cycle disorder. These developments signify significant advancements in potential therapeutic solutions for these conditions.
Seeking Alpha
Arcturus Therapeutics Advances Phase 2 Studies for ARCT-032 and ARCT-810 in Treating Cystic Fibrosis and Urea Cycle Disorder

Overview

Arcturus Therapeutics continues to push forward with its promising treatments for cystic fibrosis and urea cycle disorder.

Main Points

  • Advancement in phase 2 study for ARCT-032
  • Expansion of program for ARCT-810
  • Potential therapeutic benefits for cystic fibrosis and urea cycle disorder

Conclusion: Arcturus's ongoing efforts demonstrate a commitment to advancing medical solutions for serious genetic conditions.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe